IN8bio Inc. (INAB)
NASDAQ: INABHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
INAB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $13.60M
- EPS (TTM)
- -$1.62
- Dividend yield
- None
- 52-week range
- 0.88 – 2.73
- Day range
- 1.33 – 1.40
- Volume / Avg
- 20.92K / 59.11K
- Beta
- —
- Shares outstanding
- 9.86M
- Next earnings
- Nov 5, 2026
52-week range
INAB stock today
On Oct 8, INAB ended the session at $1.38, shedding $0.02 (1.43%), versus the S&P 500's 0.47% decline. Trading was light, with 20.92K shares changing hands, about 35% of the average daily volume. At this level, INAB sits in the middle of its 52-week range of $0.88 to $2.73: 49.5% below the high, set on Jan 16, 2026 and 56.8% above the low.
INAB is down 41.0% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 42.7%. IN8bio has posted a net loss over the last twelve months (EPS of -$1.62), so its P/E ratio is not meaningful. IN8bio's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About IN8bio
Company profileIN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Tai-Wei Ho
- Headquarters
- New York, NY
- Employees
- 18
- IPO year
- 2021
- Website
- in8bio.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$7.00+407.25%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.57
IN8bio peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KPTIKaryopharm Therapeutics Inc. | 0.60 | -6.98% | $13.61M | vs INAB |
| CNSYCerenome Inc. | 1.79 | +9.48% | $13.59M | vs INAB |
| NIKINiki BioSolutions Inc. | 4.32 | -7.10% | $13.47M | vs INAB |
| CTXRCitius Pharmaceuticals Inc. | 0.4887 | -2.47% | $13.42M | vs INAB |
| HINDVyome Holdings Inc. | 2.03 | -0.49% | $14.25M | vs INAB |
| CLRBCellectar Biosciences Inc. | 1.40 | -7.28% | $13.23M | vs INAB |
| TVRDTvardi Therapeutics Inc. | 1.08 | -1.82% | $14.41M | vs INAB |
| TPSTTempest Therapeutics Inc. | 0.77 | -2.70% | $13.01M | vs INAB |
Indexes, lists and sector
Appears in lists
IN8bio stock FAQ
What is IN8bio's stock price today?
INAB last traded at $1.38 as of Oct 8, 4:00 PM EDT, down 1.43% on the day. Prices are delayed at least 15 minutes.
Does IN8bio pay a dividend?
No. IN8bio does not currently pay a regular cash dividend.
When is IN8bio's next earnings date?
IN8bio is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.57.
Who is IN8bio's CEO?
Mr. Tai-Wei Ho is the chief executive officer of IN8bio Inc., which has about 18 employees.
Has INAB ever split its stock?
Yes. The most recent INAB stock split was a 1-for-30 split on Jun 6, 2025.
What is the INAB 52-week high?
The 52-week high for INAB is $2.73 and the 52-week low is $0.88. The stock is currently 49.5% below its high.